Assertio Therapeutics, Inc. (ASRT)
Stock Price Chart
Key Info
| Market Cap | 94.77M |
| Revenue (ttm) | 194.13M |
| Net Income (ttm) | -161.67M |
| Shares Out | 105.36M |
| EPS (ttm) | -2.23 |
| PE Ratio | n/a |
| Forward PE | 1.53 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 4, 2020 |
| Last Price | $0.900 |
| Previous Close | $0.870 |
| Change ($) | 0.030 |
| Change (%) | 3.45% |
| Day's Open | 0.860 |
| Day's Range | 0.858 - 0.940 |
| Day's Volume | 665,456 |
| 52-Week Range | 0.550 - 3.500 |
More Stats
| Market Cap | 94.77M |
| Enterprise Value | 46.66M |
| Earnings Date (est) | Aug 7, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 105.36M |
| Float | 61.33M |
| EPS (basic) | -2.29 |
| EPS (diluted) | -2.23 |
| FCF / Share | 0.52 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | 38.77% |
| Payout Ratio | n/a |
| Shares Short | 1.72M |
| Short Ratio | 1.17 |
| Short % of Float | 1.48% |
| Beta | 2.20 |
| PE Ratio | n/a |
| Forward PE | 1.53 |
| P/FCF Ratio | 2.58 |
| PS Ratio | 0.49 |
| PB Ratio | 1.21 |
| Revenue | 194.13M |
| Operating Income | -214.13M |
| Net Income | -161.67M |
| Free Cash Flow | 36.74M |
| Net Cash | 48.11M |
| Net Cash / Share | 0.46 |
| Gross Margin | 113.34% |
| Operating Margin | -110.30% |
| Profit Margin | -84.00% |
| FCF Margin | 18.93% |
| ROA | -2.61% |
| ROE | -110.51% |
| ROIC | -48.50% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 230 | 312 | 381 | 456 | 343 | 390 | 134 | 90.82 | 133 | 80.76 |
| Revenue Growth | -26.39% | -18.11% | -16.49% | 33.02% | -12.2% | 190.87% | 47.78% | -31.7% | 64.64% | - |
| Gross Profit | 220 | 293 | 308 | 368 | 275 | 375 | 127 | 84.78 | 127 | 72.67 |
| Operating Income | -194 | 43.66 | -42.18 | 24.51 | -50.40 | 237 | 9.32 | -30.35 | 70.70 | 3.63 |
| Net Income | -217 | 36.91 | -102 | -88.72 | -75.74 | 132 | 43.31 | -29.78 | 70.73 | 3.90 |
| Shares Outstanding | 70.72 | 63.79 | 62.70 | 61.30 | 60.12 | 58.29 | 56.74 | 55.89 | 54.56 | 52.53 |
| Earnings Per Share | -3.07 | 0.57 | -1.63 | -1.45 | -1.26 | 2.05 | 0.75 | -0.53 | 1.26 | 0.07 |
| EPS Growth | - | - | - | - | - | 173.33% | - | - | 1700% | - |
| Operating Cash Flow | 90.48 | 72.50 | 62.17 | 71.26 | 152 | -55.92 | 9.75 | -30.99 | 57.65 | -2.38 |
| Capital Expenditures | -1.48 | -5.36 | -0.39 | -2.86 | -1.72 | -0.60 | -1.81 | -6.88 | -0.70 | -0.18 |
| Free Cash Flow | 88.99 | 67.14 | 61.78 | 68.40 | 151 | -56.52 | 7.94 | -37.87 | 56.95 | -2.56 |
| Cash & Equivalents | 42.11 | 111 | 128 | 177 | 210 | 559 | 272 | 66.81 | 86.15 | 70.35 |
| Total Debt | 351 | 566 | 627 | 719 | 800 | 230 | - | - | - | 2.17 |
| Net Cash / Debt | -309 | -455 | -499 | -541 | -591 | 330 | 272 | 66.81 | 86.15 | 68.18 |
| Assets | 527 | 933 | 1,039 | 1,225 | 1,357 | 711 | 509 | 142 | 164 | 87.03 |
| Liabilities | 469 | 713 | 869 | 975 | 1,042 | 347 | 371 | 57.72 | 58.45 | 63.93 |
| Book Value | 57.96 | 220 | 170 | 251 | 315 | 364 | 137 | 83.94 | 106 | 23.11 |
Company Profile
Company Details
| Full Name | Assertio Therapeutics, Inc. |
| Country | United States |
| Employees | 125 |
| CEO | Todd N. Smith |
Stock Information
| Ticker Symbol | ASRT |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Unique Identifier | NASDAQ: ASRT |
| IPO Date | November 5, 1997 |
Description
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in neurology, orphan, and specialty areas in the United States. The company offers Gralise (gabapentin), a once daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks; and Zipsor (diclofenac potassium liquid filled capsules), a non-steroidal anti-inflammatory drug for treating mild to moderate acute pain. It also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to require daily, around-the-clock, and long term opioid treatment, including neuropathic pain related to diabetic peripheral neuropathy in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, the company offers long-acting cosyntropin, an alcohol-free formulation of synthetic adrenocorticotropic hormone. Assertio Therapeutics, Inc. has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois.